Content
TerrAscend's Q2 Financial Report Metrics Were Up Across The Board
Article By:
Lorimer Wilson
Read
Monday, August 14, 2023 12:30 AM EDT
TerrAscend's stock price jumped 5.6% on Friday (from $1.60 to $1.69) with the release of its Q2 financial report and is now up 19.0% so far in August and 53.6% YTD.
In this article: TSNDF
TalkMarkets Announces Company Spotlight Featuring Evogene
Article By:
TalkMarkets Newswire
Read
Thursday, June 22, 2023 4:13 PM EDT
TalkMarkets.com announces a company spotlight series featuring Evogene (NASDAQ: EVGN), an agri-tech and bio-tech company with a computational predictive biological platform technology.
In this article: EVGN
TalkMarkets Announces Company Spotlight Featuring Adamas One
Article By:
TalkMarkets Newswire
Read
Wednesday, June 14, 2023 9:15 AM EDT
TalkMarkets.com announces a company spotlight series featuring Adamas One (NASDAQ: JEWL), a leading producer of lab-grown diamonds.
In this article: JEWL
Investing In Luxury: Adamas One Unlocks The Potential For Lab-Grown Diamonds
Article By:
Shareholders Unite
Read
Tuesday, June 13, 2023 9:56 AM EDT
Adamas One (JEWL) is a highly profitable company. There is no lack of demand for lab-grown diamonds and the company has already been producing at full production capacity since March of this year.
In this article: JEWL
NIO Inc. Reports Unaudited First Quarter 2023 Financial Results
Article By:
NASDAQ GlobeNewswire
Read
Friday, June 9, 2023 9:00 AM EDT
Quarterly Total Revenues reached RMB10,676.5 million (US$1,554.6 million). Quarterly Vehicle Deliveries were 31,041 units.
In this article: NIO
Adamas One Acquires Minority Equity Stake In Artificial Intelligence Solutions Provider NexGenAI Solutions Group, Inc.
Article By:
NASDAQ GlobeNewswire
Read
Wednesday, May 31, 2023 9:15 AM EDT
Adamas to incorporate AI-driven solutions to optimize manufacturing, marketing, branding and communications related to its development of Lab-Grown Diamonds
In this article: JEWL
Inhibikase Therapeutics: A Novel And Promising Approach To Neurodegeneration And Oncology
Article By:
Bio Deep Dives
Read
Wednesday, May 24, 2023 9:55 AM EDT
IKT's heavily discounted valuation provides a compelling risk/reward given the ability to establish both safety and efficacy in Parkinson’s disease let alone any progress in oncology.
In this article: IKT
Biomica Announces Closing Of $20 Million Financing Round Led By Shanghai Healthcare Capital
Article By:
TalkMarkets Newswire
Read
Thursday, April 27, 2023 8:00 AM EDT
Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), today announced that it has closed a financing round of $20 million
In this article: EVGN
CoT Report: What They're Buying, What It Means
Article By:
Paban Pandey
Read
Sunday, April 9, 2023 12:03 AM EDT
Several OPEC+ members’ planned cuts in crude output may well have thrown the inflation-focused Fed a curve ball. When it is all said and done, markets in all probability are misreading the Fed’s resolve to bring inflation under control.
Near Intelligence Announces Fourth Quarter And Full Year 2022 Financial Results
Article By:
Business Wire
Read
Tuesday, March 28, 2023 7:16 AM EDT
Near’s fourth quarter performance provided a solid finish to the year which was highlighted by 32% annual revenue growth and 120% net revenue retention.
In this article: NIR
RenovoRx’s Principal Investigator Of Phase III Clinical Trial Discusses Positive Interim Results On Patients With Locally Advanced Pancreatic Cancer On OncologyTube
Video By:
TalkMarkets Newswire
Watch
Tuesday, March 21, 2023 11:26 AM EDT
In the interview, Dr. Michael Pishvaian discussed the trial's potential impact on the oncology community as well as how pancreatic cancer patients are treated.
In this video: RNXT
RenovoRx Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data That Support Continued Clinical Investigation Of RenovoGemTM As A Treatment Option For Locally Advanced Pancreatic Cancer
Article By:
Business Wire
Read
Wednesday, March 8, 2023 8:23 AM EDT
Renovo RX today announced promising interim data in the Phase III open label TIGeR-PaC clinical trial.
In this article: RNXT